David Irvine

Dr David Irvine is a Research Fellow at the School of Cancer Sciences, University of Glasgow, specializing in leukemia stem cell biology and targeted therapies. His research focuses on understanding drug resistance mechanisms and developing novel treatments for chronic myeloid leukemia (CML).

Research Interests:

• Leukemia stem cell persistence and therapeutic resistance
• Hedgehog and bone morphogenetic protein (BMP) signaling pathways
• Tyrosine kinase inhibitor (TKI) pharmacology
• Cancer metabolism, particularly oxidative phosphorylation in CML
• Synthetic lethality in leukemia gene targeting

Recent Research Trends: Analysis of his publications from 2010–2025 reveals sustained investigation into CML stem cell biology, TKI resistance, and novel therapeutic strategies like hedgehog pathway inhibition and RAD52 targeting. His work bridges preclinical studies and clinical trials, including contributions to CAR-T cell therapy implementation and antifibrinolytic treatment protocols.